Predictors of Direct Oral Anticoagulant Use in Northern Italy: A Population‐Based Study
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Luisa Ojeda-Fernández und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy. Hauptthemen laut MEDLINE: Anticoagulants, Practice Patterns, Physicians', Factor Xa Inhibitors, Drug Substitution. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regione Lombardia.
Abstract (Originalsprache)
Purpose
Evidence on head‐to‐head comparison between direct oral anticoagulants (DOACs) is lacking, and the reasons for choosing one type of DOAC and switching from one DOAC to another are scarce. This study investigated the use of DOACs in an unselected population in Northern Italy during a recent period.
Methods
Using the health administrative database of the Lombardy region, subjects aged 45 years and older who started DOAC therapy between 2019 and 2022 were included in the analysis. Logistic regression analysis was used to evaluate predictors associated with DOAC prescription, and results were presented as ORs with 95% CI. DOAC switching was assessed by estimating the prevalence and cumulative incidence according to the first prescribed DOAC.
Results
Overall, 159 993 new users for DOAC were identified. Apixaban users increased from 29.0% to 34.3%, whereas dabigatran users decreased from 20.7% to 11.5% over time. Across all pair‐wise comparisons, older age and female sex were predictors for edoxaban prescription. Comorbidities were mainly associated with the use of apixaban; however, dabigatran was preferred in patients with a history of ischemic heart disease or myocardial infarction and rivaroxaban in those with peripheral artery disease. Both apixaban and edoxaban were preferentially prescribed to patients with a history of bleeding. The switching rate of DOACs was 5.6% with apixaban as the most preferred drug as a second choice. Dabigatran was mainly chosen as a second DOAC after a vascular ischaemic event.
Conclusion
Given the lack of evidence on factors influencing clinician behavior in the use of DOACs, our findings provide insight into this topic in a real‐world setting. As the use of these agents increases, further evidence is needed to better explore this issue. Our data could contribute to the development of recommendations in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
- Directorate General for Health, Lombardy Region, Milano, Italy.
- Lazzate ASST Brianza, Lombardy Region, Italy.
ORCID-Profile: Luisa Ojeda-Fernández, Marta Baviera
Förderung
- Regione Lombardia
Zitieren
APA
Ojeda-Fernández, L., Agostini, G., Zanovello, A., Prada, P., Fortino, I., Augurio, C., & Baviera, M. (2025). Predictors of Direct Oral Anticoagulant Use in Northern Italy: A Population‐Based Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70300
Vancouver
Ojeda-Fernández L, Agostini G, Zanovello A, Prada P, Fortino I, Augurio C, et al. Predictors of Direct Oral Anticoagulant Use in Northern Italy: A Population‐Based Study. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70300
BibTeX
@article{OjedaFernndez2025,
author = {Ojeda-Fernández, Luisa and Agostini, Greta and Zanovello, Anna and Prada, Patrick and Fortino, Ida and Augurio, Claudia and Baviera, Marta},
title = {Predictors of Direct Oral Anticoagulant Use in Northern Italy: A Population‐Based Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70300}
}
EUVIMED